The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19

the CCC19 consortium

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background: Hospitalized patients with COVID-19 have increased risks of venous (VTE) and arterial thromboembolism (ATE). Active cancer diagnosis and treatment are well-known risk factors; however, a risk assessment model (RAM) for VTE in patients with both cancer and COVID-19 is lacking. Objectives: To assess the incidence of and risk factors for thrombosis in hospitalized patients with cancer and COVID-19. Methods: Among patients with cancer in the COVID-19 and Cancer Consortium registry (CCC19) cohort study, we assessed the incidence of VTE and ATE within 90 days of COVID-19–associated hospitalization. A multivariable logistic regression model specifically for VTE was built using a priori determined clinical risk factors. A simplified RAM was derived and internally validated using bootstrap. Results: From March 17, 2020 to November 30, 2020, 2804 hospitalized patients were analyzed. The incidence of VTE and ATE was 7.6% and 3.9%, respectively. The incidence of VTE, but not ATE, was higher in patients receiving recent anti-cancer therapy. A simplified RAM for VTE was derived and named CoVID-TE (Cancer subtype high to very-high risk by original Khorana score +1, VTE history +2, ICU admission +2, D-dimer elevation +1, recent systemic anti-cancer Therapy +1, and non-Hispanic Ethnicity +1). The RAM stratified patients into two cohorts (low-risk, 0–2 points, n = 1423 vs. high-risk, 3+ points, n = 1034) where VTE occurred in 4.1% low-risk and 11.3% high-risk patients (c statistic 0.67, 95% confidence interval 0.63–0.71). The RAM performed similarly well in subgroups of patients not on anticoagulant prior to admission and moderately ill patients not requiring direct ICU admission. Conclusions: Hospitalized patients with cancer and COVID-19 have elevated thrombotic risks. The CoVID-TE RAM for VTE prediction may help real-time data-driven decisions in this vulnerable population.

Original languageEnglish (US)
Pages (from-to)2522-2532
Number of pages11
JournalJournal of Thrombosis and Haemostasis
Volume19
Issue number10
DOIs
StatePublished - Oct 2021

Keywords

  • clinical decision rules
  • COVID-19
  • SARS-CoV-2
  • thrombosis
  • venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'The CoVID-TE risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19'. Together they form a unique fingerprint.

Cite this